Transcript:
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026ByKyle Doherty June 9th 2026
Adjuvant Durvalumab Plus Tremelimumab Shows DFS Advantage Over Active Monitoring in Resected RCCByKyle Doherty May 30th 2026
Experts Recap the Most Notable Data in GU Cancers Presented During the 2026 AUA Annual Meeting ByKyle Doherty May 27th 2026